Page 3 - Ib Communications News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Advances rollout of POCare Platform and POCare Therapies...

GERMANTOWN, Md., Oct. 30, 2023 -- Orgenesis Inc. , a global biotech company working to unlock the full potential of cell and gene therapies , today announced that it has withdrawn its previously...

REGULATED INFORMATION Following the in-principle agreement reached with its main creditors in the context of ongoing equity raise process, the focus of BioSenic is now to proceed with fundraising, allowing to start its phase 3 international clinical trial with oral arsenic trioxide (ATO) in the first-line treatment of chronic Graft-versus-Host-Disease (cGvHD). Mont-Saint-Guibert, Belgium, October 25, 2023, 7.00 am CEST – BioSenic provides third quarter 2023 Business Update Following the in-princ

BioSenic performs further analysis of its phase 2 clinical trial data, leading to an optimal administration scheme for its next late-stage trial of arsenic trioxide in cGvHD New post-hoc analysis...

INSIDE INFORMATIONS BioSenic publishes new evidence of beneficial effects of arsenic trioxide treatment supporting clinical trial for systemic sclerosis Arsenic trioxide therapeutic potential...